

# Contents

## CHAPTER 1

### **Pathogenesis of Viral Infections. J. HAY and M. J. BARTKOSKI, JR.**

With 22 Figures

A. Introduction . . . . .	1
I. Defective Interfering Particles . . . . .	2
II. Integration of Viral Genomes . . . . .	3
B. Adenoviruses . . . . .	3
I. Structure and Replication . . . . .	4
II. Adenovirus Infections . . . . .	8
C. Arenaviruses . . . . .	9
D. Coronaviruses . . . . .	12
E. Viral Hepatitis . . . . .	14
I. Hepatitis A . . . . .	15
II. Hepatitis B . . . . .	15
F. Herpesviruses . . . . .	18
I. Herpes Simplex Viruses 1 and 2 . . . . .	18
II. Herpes Simplex Virus Infections . . . . .	22
III. Cytomegalovirus . . . . .	24
IV. Varicella Zoster Virus . . . . .	25
V. Epstein-Barr Virus . . . . .	26
G. Orthomyxoviruses . . . . .	29
I. Influenza A and B Viruses . . . . .	29
II. Influenza C Virus . . . . .	33
III. Influenza Infections . . . . .	33
H. Human Papillomavirus . . . . .	34
J. Paramyxoviruses . . . . .	35
I. Measles Infection . . . . .	38
II. Persistent Measles Infection . . . . .	39
III. Mumps Infection . . . . .	40
IV. Parainfluenza Infection . . . . .	40
K. Picornaviruses . . . . .	41
I. Structure and Replication . . . . .	41
II. Picornavirus Infections . . . . .	43
L. Reoviruses . . . . .	45
M. RNA Tumor Viruses . . . . .	48

N. Rhabdoviruses . . . . .	50
I. Structure and Replication . . . . .	51
II. Rabies Virus Infection . . . . .	53
O. Rotaviruses . . . . .	54
I. Structure and Replication . . . . .	55
II. Rotavirus Infections . . . . .	57
P. Poxviruses . . . . .	57
I. Structure and Replication . . . . .	58
II. Poxvirus Infections . . . . .	60
Q. Togaviruses and Bunyaviruses . . . . .	61
I. Togaviruses . . . . .	62
II. Bunyaviruses . . . . .	65
R. Slow Viruses . . . . .	67
I. Unconventional Agents . . . . .	67
II. Conventional Agents . . . . .	69
References . . . . .	70

## Part A

### CHAPTER 2

#### **Pyrimidine Nucleosides with Selective Antiviral Activity.**

P. H. FISCHER and W. H. PRUSOFF. With 1 Figure

A. Introduction . . . . .	95
B. 5-Halogenated Pyrimidine 2'-Deoxyribonucleosides . . . . .	98
I. 5-Iodo-2'-Deoxyuridine . . . . .	98
1. Synthesis . . . . .	98
2. Antiviral Activity . . . . .	98
3. Effects on Normal Cells . . . . .	98
4. Mechanism of Action . . . . .	99
II. 5-Trifluoromethyl-2'-Deoxyuridine . . . . .	100
1. Synthesis . . . . .	100
2. Antiviral Activity . . . . .	100
3. Effects on Normal Cells . . . . .	101
4. Mechanism of Action . . . . .	101
III. 5-Iodo-2'-Deoxycytidine . . . . .	101
1. Synthesis . . . . .	101
2. Antiviral Activity . . . . .	102
3. Effects on Normal Cells . . . . .	102
4. Mechanism of Action . . . . .	102
C. Other 5-Substituted 2'-Deoxyuridine Derivatives . . . . .	103
I. 5-Ethyl-2'-Deoxyuridine . . . . .	103
1. Antiviral Activity . . . . .	103
2. Effects on Normal Cells . . . . .	103
3. Mechanism of Action . . . . .	103

II. 5-Propyl-2'-Deoxyuridine . . . . .	103
1. Antiviral Activity . . . . .	103
2. Mechanism of Action . . . . .	104
III. E-5-(2-Bromovinyl)-2'-Deoxyuridine (BVdUrd) . . . . .	104
IV. 5-Methoxymethyl-2'-Deoxyuridine . . . . .	104
V. Miscellaneous 5-Substituted 2'-Deoxyuridine Derivatives . . . . .	105
D. Pyrimidine Nucleosides with an Altered Ring Structure . . . . .	105
E. Pyrimidine Nucleosides with an Altered Carbohydrate Moiety . . . . .	105
I. Arabinofuranosylthymine . . . . .	105
1. Antiviral Activity . . . . .	105
2. Effects on Normal Cells . . . . .	105
3. Mechanism of Action . . . . .	106
II. Arabinofuranosylcytosine . . . . .	106
III. 5-Iodo-5'-Amino-2',5'-Dideoxyuridine . . . . .	107
1. Synthesis . . . . .	107
2. Antiviral Activity . . . . .	107
3. Mechanism of Action . . . . .	107
IV. 1-(2-Deoxy-2-Fluoro- $\beta$ -D-Arabinofuranosyl)-5-Iodocytosine . . . . .	108
References . . . . .	108

## CHAPTER 3

**Purines.** N.-H. PARK and D. PAVAN-LANGSTON. With 9 Figures

A. Introduction . . . . .	117
B. 9- $\beta$ -D-Arabinofuranosyladenine . . . . .	117
I. Introduction and History . . . . .	117
II. Chemistry . . . . .	118
III. Antiviral Spectrum . . . . .	118
IV. Mechanism of Action . . . . .	119
V. Metabolism, Distribution, and Excretion . . . . .	121
VI. Clinical and Experimental Therapeutic Aspects . . . . .	123
VII. Untoward Effects . . . . .	123
VIII. Analogs of Ara-A . . . . .	123
IX. Perspectives . . . . .	124
C. 9-(2-Hydroxyethoxymethyl)guanine . . . . .	125
I. Introduction and History . . . . .	125
II. Chemistry . . . . .	126
III. Antiviral Spectrum . . . . .	126
IV. Mechanism of Action . . . . .	127
V. Metabolism, Distribution, and Excretion . . . . .	129
VI. Clinical and Experimental Therapeutic Aspects . . . . .	130
VII. Untoward Effects . . . . .	130
VIII. Perspectives . . . . .	131
References . . . . .	131

## CHAPTER 4

**Amantadine and Its Derivatives.** J. L. SCHULMAN. With 1 Figure

A. Introduction and History . . . . .	137
B. Chemical Structure . . . . .	137
C. Spectrum of Antiviral Activity . . . . .	137
D. Mechanism of Action . . . . .	138
E. Pharmacology . . . . .	139
I. Absorption . . . . .	139
II. Metabolism . . . . .	139
III. Side Effects . . . . .	139
F. Animal Studies . . . . .	140
I. Prophylaxis . . . . .	140
II. Treatment . . . . .	141
G. Clinical Trials . . . . .	141
I. Prophylaxis . . . . .	141
II. Treatment . . . . .	142
H. Resistant Variants . . . . .	142
J. Conclusions and Perspectives . . . . .	143
References . . . . .	144

## CHAPTER 5

**The Thiosemicarbazones.** C. J. PFAU. With 24 Figures

A. Introduction . . . . .	147
B. History . . . . .	147
C. Chemistry . . . . .	148
I. Aryl Thiosemicarbazones . . . . .	149
II. Quinoline, Pyridine, and Thiophene Thiosemicarbazones . . . . .	151
III. Isatin- $\beta$ -Thiosemicarbazones . . . . .	152
1. Substitution in the Aromatic Ring . . . . .	153
2. <i>N</i> -Substitution in the Pyrrolidine Ring . . . . .	153
3. Modification of the Pyrrolidine Ring . . . . .	154
4. Modification of the TSC Side Chain . . . . .	155
5. Other Compounds . . . . .	155
IV. Isatin- $\beta$ -4',4'-Dialkylthiosemicarbazones . . . . .	156
V. Isatin- $\beta$ -Isothiosemicarbazones . . . . .	156
VI. Thiazole Thiosemicarbazones . . . . .	157
VII. Pyrrolidine and Pyrazolone Thiosemicarbazones . . . . .	158
VIII. Noncyclic Thiosemicarbazones . . . . .	159
IX. Miscellaneous Thiosemicarbazones . . . . .	160
D. Virus-Inhibitory Spectrum . . . . .	161
I. Aryl Thiosemicarbazones . . . . .	161
II. Quinoline, Pyridine, and Thiophene Thiosemicarbazones . . . . .	162
III. Isatin- $\beta$ -Thiosemicarbazones . . . . .	163
IV. Isatin- $\beta$ -4',4'-Dialkylthiosemicarbazones . . . . .	167
V. Isatin- $\beta$ -Isothiosemicarbazones . . . . .	168
VI. Thiazole Thiosemicarbazones . . . . .	168

VII. Pyrrolidine and Pyrazolone Thiosemicarbazones . . . . .	168
VIII. Noncyclic Thiosemicarbazones . . . . .	168
IX. Miscellaneous Thiosemicarbazones . . . . .	168
E. Effects on Normal Cells . . . . .	169
I. Aryl Thiosemicarbazones . . . . .	169
II. Quinoline, Pyridine, and Thiopene Thiosemicarbazones . . . . .	169
III. Isatin- $\beta$ -Thiosemicarbazones . . . . .	169
IV. Isatin- $\beta$ -4',4'-Dialkylthiosemicarbazones . . . . .	170
V. Isatin- $\beta$ -Isothiosemicarbazones . . . . .	170
VI. Thiazole Thiosemicarbazones . . . . .	170
VII. Pyrrolidine and Pyrazolone Thiosemicarbazones . . . . .	171
VIII. Noncyclic Thiosemicarbazones . . . . .	171
IX. Miscellaneous Thiosemicarbazones . . . . .	172
F. Mechanism of Action . . . . .	172
I. Aryl Thiosemicarbazones . . . . .	172
II. Quinoline, Pyridine, and Thiopene Thiosemicarbazones . . . . .	173
III. Isatin- $\beta$ -Thiosemicarbazones . . . . .	175
1. Adsorption, Penetration, and Uncoating . . . . .	176
2. Transcription . . . . .	177
3. Translation . . . . .	178
4. Replication . . . . .	179
5. Proteins and Viral Assembly . . . . .	180
IV. Isatin- $\beta$ -4',4'-Dialkylthiosemicarbazones . . . . .	185
V. Isatin- $\beta$ -Isothiosemicarbazones . . . . .	186
VI. Thiazole Thiosemicarbazones . . . . .	186
VII. Pyrrolidine and Pyrazolone Thiosemicarbazones . . . . .	187
VIII. Noncyclic Thiosemicarbazones . . . . .	187
IX. Miscellaneous Thiosemicarbazones . . . . .	188
G. Animal Studies . . . . .	188
I. Aryl Thiosemicarbazones . . . . .	188
II. Quinoline, Pyridine, and Thiophene Thiosemicarbazones . . . . .	189
III. Isatin- $\beta$ -Thiosemicarbazones . . . . .	190
IV. Isatin- $\beta$ -4',4'-Dialkylthiosemicarbazones . . . . .	193
V. Isatin- $\beta$ -Isothiosemicarbazones . . . . .	193
VI. Thiazole Thiosemicarbazones . . . . .	193
H. Clinical Studies . . . . .	194
I. N <sub>1</sub> -Methylisatin- $\beta$ -Thiosemicarbazone . . . . .	194
II. 3-Methyl-4-Bromo-5-Formylisothiazole Thiosemicarbazone . . . . .	197
J. Perspectives . . . . .	197
References . . . . .	198

## CHAPTER 6

**Interferon and Its Inducers.** P. B. SEHGAL, L. M. PFEFFER, and I. TAMM.

With 5 Figures

A. Preface . . . . .	205
B. Introduction . . . . .	205

C. Production and Characterization of Human Interferons . . . . .	207
I. Classification . . . . .	207
II. Assay . . . . .	209
III. Production . . . . .	209
1. Human Leukocyte Interferon . . . . .	209
2. Human Fibroblast Interferon . . . . .	210
3. Human Lymphoblastoid Interferon . . . . .	211
4. Alternative Sources . . . . .	211
IV. Characterization . . . . .	212
1. Protein Purification and Sequencing . . . . .	212
2. Cloning of cDNA Corresponding to Interferon mRNA Species . . . . .	215
V. Mechanisms of Interferon Induction . . . . .	218
1. General Comments . . . . .	218
2. Interferon Induction by Viral Inducers . . . . .	219
3. Interferon Induction by Synthetic Polynucleotides . . . . .	221
4. Interferon Induction by Other Stimuli . . . . .	223
5. Genetics of Interferon Induction . . . . .	224
6. Characterization of Interferon mRNA Species and Their Transcription Units . . . . .	225
VI. The Regulation of Interferon Production . . . . .	226
1. Priming . . . . .	229
2. Superinduction . . . . .	230
D. Spectrum of Antiviral Activity . . . . .	233
E. Mechanisms of Antiviral Action of Interferon . . . . .	234
I. Interferon Binding . . . . .	235
II. Induction of the Antiviral State . . . . .	236
III. Effects on the Cell Surface . . . . .	238
IV. Effects on Translation-Inhibitory Enzymes . . . . .	239
1. Oligo(A) Synthetase . . . . .	239
2. dsRNA-Dependent Kinase . . . . .	240
3. Cap Methylation of Viral mRNA . . . . .	242
4. The tRNA Effect . . . . .	243
5. Postscript: The Problem of Selectivity . . . . .	243
V. Effects of Interferon in Various Virus-Host Cell Systems . . . . .	243
1. Viral Uncoating . . . . .	243
2. Viral Transcription . . . . .	244
3. Viral Protein Synthesis . . . . .	245
4. Viral Assembly or Release . . . . .	246
F. Diversity of Interferon Action: Effects on Normal and Transformed Cells . . . . .	247
I. Cell Proliferation . . . . .	248
II. Cell Functions . . . . .	250
G. Pharmacokinetics of Interferons . . . . .	252
H. Efficacy of Interferons in Animal Models . . . . .	253
I. Antiviral Studies . . . . .	253
II. Antitumor Studies . . . . .	255
1. Virus-Induced Tumors . . . . .	255
2. Virus- and Radiation-Related "Spontaneous" Tumors . . . . .	255
3. Transplantable Tumors . . . . .	256

II. Toxicity of Interferon in Animals . . . . .	256
J. Efficacy of Interferons in Humans . . . . .	256
I. Antiviral Studies . . . . .	256
II. Antitumor Studies . . . . .	266
III. Toxicity of Interferon in Humans . . . . .	267
K. Interferon Inducers . . . . .	267
I. High Molecular Weight Substances . . . . .	270
1. Antiviral Effects . . . . .	270
2. Antitumor Effects . . . . .	273
II. Low Molecular Weight Substances . . . . .	277
1. Antiviral Effects . . . . .	277
2. Antitumor Effects . . . . .	281
L. Perspectives . . . . .	281
References . . . . .	283

## CHAPTER 7

**Immunotherapy and Immunoregulation.** H. FRIEDMAN and S. SPECTER

A. Introduction . . . . .	313
B. Immunity and Virus Infections . . . . .	314
C. Antiviral Agents . . . . .	316
I. Microbial Products . . . . .	316
1. Protozoa . . . . .	316
2. Gram-Negative Bacteria . . . . .	317
3. Gram-Positive Bacteria . . . . .	318
4. Mycobacteria . . . . .	320
II. Products of the Immune System . . . . .	321
1. Immune Globulins . . . . .	322
2. Thymic Hormones . . . . .	323
3. Transfer Factor . . . . .	324
4. Immune RNA . . . . .	324
5. Interferon . . . . .	325
III. Synthesized Immunostimulants . . . . .	325
1. Levamisole . . . . .	325
2. Vitamins . . . . .	326
3. Tilorone . . . . .	327
4. Pyran . . . . .	327
5. Inosiplex (Isoprinosine) . . . . .	328
D. Potential of Immunostimulants as Antiviral Agents . . . . .	329
References . . . . .	330

**Part B**

## CHAPTER 8

**Guanidine.** D. R. TERSHAK, F. H. YIN, and B. D. KORANT. With 9 Figures

A. Introduction and History . . . . .	343
B. Synthesis and Properties of Picornavirus Proteins . . . . .	343

I. "Shutoff" of Host Cell Protein Synthesis . . . . .	344
II. Synthesis of Viral Proteins . . . . .	344
III. Mapping of the Viral Genome . . . . .	347
IV. Isolation of Viral Polypeptides . . . . .	348
C. Replication of Viral RNA . . . . .	348
I. Viral RNA Structure . . . . .	348
II. Viral Polymerase . . . . .	351
D. Chemistry of Guanidine . . . . .	352
E. Effects of Guanidine on Virus Replication . . . . .	352
I. Spectrum of Inhibited Viruses . . . . .	352
II. Effects on Cells . . . . .	353
III. Stage of Viral Growth Inhibited by Guanidine . . . . .	354
IV. Guanidine-Suppressive Compounds . . . . .	356
V. Site of Action of Guanidine . . . . .	358
VI. Mechanism of Action of Guanidine . . . . .	359
1. Previous Studies . . . . .	359
2. Effects on Poliovirus Polymerase in Vitro . . . . .	361
3. Probable Mode of Action of Guanidine . . . . .	367
F. Guanidine as a Therapeutic Agent in Animals . . . . .	368
G. Clinical Nonvirologic Studies . . . . .	369
References . . . . .	370

## CHAPTER 9

**Benzimidazoles.** H. J. EGGERS. With 22 Figures

A. Introduction and Historical Remarks . . . . .	377
B. 2-( $\alpha$ -Hydroxybenzyl)-Benzimidazole . . . . .	378
I. Virus-Inhibitory Spectrum . . . . .	379
II. Effects of HBB on Uninfected Cells . . . . .	381
III. Kinetics of Antiviral Action, Effects on Viral Replication, and Mechanism of Action . . . . .	383
1. Kinetic Aspects of Action . . . . .	383
2. Effects on the Virus Replication Cycle . . . . .	383
3. Mechanism of Action . . . . .	388
IV. HBB Resistance and Dependence: Genetics of the System . . . . .	388
V. Rescue . . . . .	391
VI. Superadditive Antiviral Effects of HBB and Guanidine . . . . .	391
VII. Effects of HBB on Enterovirus-Infected Cells . . . . .	394
C. HBB and Guanidine Chemotherapy in Animals . . . . .	395
I. Description of the Mouse System: Successful Treatment of Entero- virus-Infected Animals . . . . .	395
II. Failure of Drug-Resistant Mutants to Emerge in Animals . . . . .	397
III. The Importance of Drug Distribution, Metabolism, and Elimination on Therapeutic Efficacy . . . . .	398
1. Introduction . . . . .	398
2. Distribution and Excretion of HBB in the Mouse: Effects of Age . . . . .	400



3. Metabolic Pathway of HBB in the Mouse and in Isolated Hepatocytes . . . . .	403
4. Distribution and Excretion of Guanidine·HCl in the Mouse . . . . .	403
5. Experiments to Define Optimum Treatment . . . . .	404
6. Treatment of Mice Infected with Coxsackievirus B4 and Poliovirus 2 . . . . .	405
7. Late Treatment When First Symptoms Have Appeared: Combined Effects of D-HBB, Guanidine, and Virus-Specific Antiserum . . . . .	405
D. Chemical Derivatives of HBB and Their Antiviral Activity in Cell Culture and in the Organism . . . . .	407
I. Structure–Activity Studies . . . . .	407
II. 1-Propyl-2-( $\alpha$ -Hydroxybenzyl)-Benzimidazole (1-Propyl-HBB) and Its Hydrochloride Salt . . . . .	408
III. 2-( $\alpha$ -Methyl- $\alpha$ -Hydroxybenzyl)-Benzimidazole Hydrochloride ( $\alpha$ -Methyl-HBB·HCl) . . . . .	409
IV. 1,2-bis-(5-Methoxy-2-Benzimidazolyl)-1,2-Ethanediol (1,2-bis-Benzimidazole) . . . . .	410
V. 2-Amino-1-(Isopropylsulfonyl)-6-Benzimidazole Phenyl Ketone Oxime . . . . .	412
E. Conclusions . . . . .	413
References . . . . .	413

## CHAPTER 10

**Arildone: A  $\beta$ -Diketone.** J. J. MC SHARRY and F. PANCIC. With 12 Figures

A. Introduction . . . . .	419
B. Chemical Structure and Synthesis . . . . .	419
C. Antiviral Effects . . . . .	421
I. In Vitro Studies . . . . .	421
1. Inhibition of Cytopathic Effects in Cell Culture . . . . .	421
2. Plaque Reduction Tests . . . . .	421
3. Effect of Virus Yield . . . . .	423
II. In Vivo Studies Against Herpes Simplex Virus . . . . .	424
1. Arildone in DMSO . . . . .	424
2. Arildone in Cream . . . . .	427
D. Mode of Action . . . . .	428
I. Herpes Simplex Virus . . . . .	428
II. Poliovirus . . . . .	430
E. Metabolism . . . . .	433
I. In Vitro Studies . . . . .	434
1. Metabolism by CATR Cells . . . . .	434
II. In Vivo Studies . . . . .	435
1. Disposition in Laboratory Animals . . . . .	435
2. Metabolism in Laboratory Animals . . . . .	437

F. Toxicology . . . . .	438
I. In Vitro Studies . . . . .	439
1. Mutagenic Evaluation of Arildone . . . . .	439
2. Effect of Arildone on Cellular Macromolecular Synthesis . . . . .	439
3. Effect of Arildone and Its Metabolites on Cell Growth . . . . .	440
II. In Vivo Studies . . . . .	441
G. Summary and Perspectives . . . . .	442
References . . . . .	443

## CHAPTER 11

**Phosphonoacetic Acid.** L. R. OVERBY. With 9 Figures

A. Introduction and History . . . . .	445
B. DNA Polymerases . . . . .	446
I. Cellular DNA Polymerases . . . . .	446
II. Herpesvirus DNA Polymerase . . . . .	448
C. Chemistry . . . . .	448
I. Structure . . . . .	448
II. Structure–Activity Relationships . . . . .	449
1. Analogs . . . . .	449
2. Phosphonoformic Acid . . . . .	452
D. Spectrum of Activity . . . . .	454
I. Virus Replication in Tissue Culture . . . . .	455
1. Productive Infections . . . . .	455
2. Transformed Cells . . . . .	456
II. Normal Cells . . . . .	457
III. Animal Models . . . . .	461
1. Cutaneous Herpesvirus Infections . . . . .	461
2. Ocular Herpesvirus Infections . . . . .	462
3. Herpes Genitalis . . . . .	462
4. Herpesvirus Infections of the Central Nervous System . . . . .	465
5. Systemic Herpesvirus Infections . . . . .	467
6. Latent Herpesvirus Infections . . . . .	467
7. Varicella Infections . . . . .	468
8. Lymphoproliferative Disease . . . . .	468
9. Nonherpesvirus Infections . . . . .	468
10. Summary . . . . .	468
E. Pharmacologic and Clinical Studies . . . . .	468
I. Metabolism . . . . .	469
II. Toxicology . . . . .	469
III. Clinical Pharmacology . . . . .	469
F. Mechanism of Action . . . . .	470
I. Inhibition of Herpesvirus-Induced DNA Polymerase . . . . .	470
II. Genetic Resistance . . . . .	471
G. Summary and Perspectives . . . . .	472
References . . . . .	473

## CHAPTER 12

**Natural Products.** P. E. CAME and B. A. STEINBERG. With 17 Figures

A. Introduction	479
B. Amino Acids	479
I. Lysine	480
II. Phenylalanine and Phenylalanine Analogs	481
III. Methionine and Methionine Analogs	484
IV. Miscellaneous Amino Acids and Analogs	486
C. Vitamin C	488
D. Flavonoids	489
E. Polysaccharides	490
I. Sulfated Polysaccharides	490
II. Heparin	492
III. Intestinal Mucopolysaccharides	492
F. Substances from Microorganisms	493
I. Fungal Products	493
1. Aphidicolin	493
2. Cordycepin	494
3. Cytochalasin B	495
4. Gliotoxin, Aranotin, Sporidesmin, and Chetomin	495
5. Mycophenolic Acid	497
6. Tenuazonic Acid	497
II. Bacterial Products	497
1. Streptomyces	497
2. Other Bacteria	501
G. Substances from Botanical Sources	502
I. Alkaloids	503
II. Tannins	504
III. Lignosulfonates	505
IV. Other Substances	505
1. $\alpha$ -Aminitin	506
2. Calcium Elenolate	506
3. Glycyrrhizic Acid	506
H. Substances from Marine Flora and Fauna	507
I. Other Substances	508
I. Vitamin A	508
II. Milk	508
III. Mosquito Tissues	509
IV. Cobra Venom	509
V. Neuraminidase Inhibitors	510
References	511

## CHAPTER 13

**Rifamycins.** C. GURGO, S. BRIDGES, and M. GREEN. With 2 Figures

A. Introduction	519
B. Activity of Rifamycins on Bacteria	520

I. Structural Requirements for Activity . . . . .	520
II. Mechanism of Inhibition of RNA Polymerase . . . . .	520
III. Effects on Psittacosis–Lymphogranuloma–Trachoma Agents . . . . .	522
C. Activity of Rifamycins on Bacterial Viruses . . . . .	522
I. Effect on DNA Bacteriophages . . . . .	522
II. Effect on RNA Bacteriophages . . . . .	523
D. Activity of Rifamycins on Mammalian Viruses . . . . .	524
I. Growth Inhibition of Mammalian Viruses by Rifampicin . . . . .	524
II. Mechanism of Vaccinia Virus Growth Inhibition by Rifampicin . . . . .	525
1. Effect on DNA Synthesis of Vaccinia-Infected Cells . . . . .	525
2. Effect on mRNA Synthesis . . . . .	526
3. Effect on Protein Synthesis . . . . .	527
4. Effect on Virus Assembly . . . . .	527
5. Inhibition of Precursor Polypeptide Cleavage . . . . .	530
6. Antivaccinia Activity of Various Rifamycin Derivatives . . . . .	530
7. Effect of Rifampicin on Experimental Vaccinia Infections . . . . .	531
III. Effect of Rifampicin on DNA Viruses Other Than Vaccinia . . . . .	531
1. Herpesviruses . . . . .	531
2. Adenoviruses . . . . .	532
IV. Effect of Rifampicin on RNA Viruses Other Than Retroviruses . . . . .	532
1. Picornaviruses . . . . .	532
2. Vesicular Stomatitis Virus . . . . .	533
V. Inhibition of Retrovirus Functions by Rifamycins . . . . .	533
1. Search for Selective Inhibitors of the Reverse Transcriptase . . . . .	534
2. Correlation Between Lipophilicity and Antipolymerase Activity . . . . .	536
3. Mechanism of Inhibition of the Reverse Transcriptase . . . . .	537
4. Effects of Rifamycins on Virus Replication and Cell Trans- formation . . . . .	538
E. Pharmacology of Rifampicin . . . . .	543
F. Antiviral Activity of Other Ansamycins . . . . .	543
I. Streptovaricins . . . . .	544
1. Effects on Vaccinia Virus . . . . .	545
2. Effect on Retrovirus Functions . . . . .	545
II. Tolypomycins . . . . .	546
III. Geldanamycin and Related Compounds . . . . .	546
G. Concluding Remarks . . . . .	546
References . . . . .	548
<b>Subject Index . . . . .</b>	<b>557</b>